Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - Supportive and palliative care

1488O - Cancer risk in individuals with intellectual disability


21 Sep 2021


Proffered Paper session - Supportive and palliative care


Supportive and Palliative Care

Tumour Site


Qianwei Liu


Annals of Oncology (2021) 32 (suppl_5): S1096-S1101. 10.1016/annonc/annonc710


Q. Liu1, H. Adami2, A. Reichenberg3, A. Kolevzon3, F. Fang4, S. Sandin5

Author affiliations

  • 1 Institute Of Environmental Medicine, Karolinska Institutet, 171 77 - Stockholm/SE
  • 2 Department Of Epidemiology, Harvard T.H. Chan School of Public Health, 02115 - Boston/US
  • 3 Department Of Psychiatry, Ichan School of Medicine at Mount Sinai, 10029 - New York/US
  • 4 Institute Of Environmental Medicine, Karolinska Institutet, 17177 - Solna/SE
  • 5 Department Of Medical Epidemiology And Biostatistics, Karolinska Institutet, 171 77 - Stockholm/SE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1488O


A large knowledge gap exists about the risk of cancer in individuals with intellectual disability (ID).


We conducted a population-based cohort study of more than 3.5 million Swedish children born to mothers from the Nordic countries, including 27,956 (0.8%) clinically ascertained cases of ID, born from 1974 to 2013, to investigate the association between ID and risk of cancer. Incident cancers were identified from the Swedish Cancer Register. We used Cox regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of cancer in relation to ID while performing detailed adjustment for potential confounding. We analyzed by ID severity and ID type (idiopathic or syndromic) separately. To evaluate potential familial confounding, we further performed a sibling-comparison.


We found a statistically significantly increased risk for any cancer (HR 1.57; 95% CI 1.35-1.82), as well as for several cancer types, including cancers in esophagus (HR 28.4, 95% CI 6.2-130.6), stomach (HR 6.1, 95% CI 1.5-24.9), small intestine (HR 12.0, 95% CI 2.9-50.1), colon (HR 2.0, 95% CI 1.0-4.1), pancreas (HR 6.0, 95% CI 1.5-24.8), uterus (HR 11.7, 95% CI 1.5-90.7), kidney (HR 4.4, 95% CI 2.0-9.8), central nervous system (HR 2.7, 95% CI 2.0-3.7), and other or unspecified sites (HR 4.8, 95% CI 1.8-12.9), as well as acute lymphoid leukemia (HR 2.4, 95% CI 1.3-4.4) and acute myeloid leukemia (HR 3.0, 95% CI 1.4-6.4). The risk increase was not modified by ID severity or sex but was higher for syndromic ID. Results from sibling-comparison spoke against familial confounding.


Individuals with ID show an increased risk for developing cancer. The association could not be explained by shared genetics or familial confounders between ID and cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

F. Fang and S. Sandin.


This study was supported by the European Union’s Horizon 2020 research and innovation programme, the Swedish Cancer Society, the Swedish Research Council for Health, Working Life and Welfare, and the China Scholarship Council.


A. Kolevzon: Financial Interests, Institutional, Funding, Research Support: AMO Pharma; Non-Financial Interests, Personal and Institutional, Advisory Role, Consult: Ovid Therapeutics, Acadia Pharmaceuticals, Alkermes, Jaguar Health, Ritrova. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.